Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mono Pharmacare's revenue for the
six
months ended in Sep. 2025 was ₹663 Mil.
Its revenue for the trailing twelve months (TTM) ended in Sep. 2025 was ₹1,475 Mil.
Mono Pharmacare's Revenue per Share for the
six
months ended in Sep. 2025 was ₹32.34.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was ₹78.21.
Warning Sign:
Mono Pharmacare Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Mono Pharmacare was -3.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 65.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 5 years, Mono Pharmacare's highest 3-Year average Revenue per Share Growth Rate was 70.80% per year. The lowest was 65.70% per year. And the median was 68.25% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Mono Pharmacare Revenue Related Terms
Mono Pharmacare Revenue Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's Revenue distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹1,475 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mono Pharmacare (NSE:MONOPHARMA) has a Revenue of ₹1,475 Mil as of Sep. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Mono Pharmacare and its competitors.
Is Mono Pharmacare's Revenue too high?
Mono Pharmacare's current Revenue is ₹1,475 Mil. Overall, Mono Pharmacare has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Revenue compare to competitors?
Mono Pharmacare's Revenue of ₹1,475 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Mono Pharmacare and its competitors. Mono Pharmacare's current Revenue is ₹1,475 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Revenue of ₹1,475 Mil. The current Revenue is ₹1,475 Mil. Mono Pharmacare's overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Revenue is ₹1,475 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
21GF Score
Get the complete analysis for NSE:MONOPHARMA
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
